English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12274/13174 (93%)
Visitors : 1755473      Online Users : 327
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/16433


    Title: Development of potent and selective inhibitors of methylenetetrahydrofolate dehydrogenase 2 for targeting acute myeloid leukemia: Sar, structural insights, and biological characterization
    Authors: Chang, HH;Lee, LC;Hsu, T;Peng, YH;Huang, CH;Yeh, TK;Lu, CT;Huang, ZT;Hsueh, CC;Kung, FC;Lin, LM;Huang, YC;Wang, YH;Li, LH;Tang, YC;Chang, L;Hsieh, CC;Jiaang, WT;Kuo, CC;Wu, SY
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: Methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2), a pivotal mitochondrial enzyme in one-carbon metabolism, is significantly upregulated in various cancers but minimally expressed in normal proliferating cells. In contrast, MTHFD1, which performs similar functions, is predominantly expressed in normal cells. Therefore, targeting MTHFD2 with selective inhibitors holds promise for a broader therapeutic window with reduced toxicity and fewer side effects. This study identified selective 2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl ureido-based derivatives through systematic chemical modifications and SAR studies. Structural biology investigations revealed substitutions in the phenyl ring and tail region modulate potency and selectivity toward MTHFD2. Additionally, a comprehensive cell screening platform revealed acute myeloid leukemia cells with FLT3 internal tandem duplication mutations are particularly sensitive to these inhibitors. Furthermore, synergistic effects were observed when combining potential compounds with Alimta. Compound 16e emerged as a leading candidate, demonstrating superior inhibition and selectivity for MTHFD2, favorable pharmacokinetics, and potent antitumor efficacy in MOLM-14 xenograft models.
    Date: 2024-11-26
    Relation: Journal of Medicinal Chemistry. 2024 Nov 26;67(23):21106-21125.
    Link to: http://dx.doi.org/10.1021/acs.jmedchem.4c01775
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001363868900001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85210297623
    Appears in Collections:[蔣維棠] 期刊論文
    [郭靜娟] 期刊論文
    [伍素瑩] 期刊論文
    [葉燈光] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI001363868900001.pdf7524KbAdobe PDF3View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback